Summary of Belite Bio Conference Call Company Overview - **Company**: Belite Bio (NasdaqCM:BLTE) - **Product**: Tinlarebant, an oral treatment for Stargardt disease Industry Context - **Disease**: Stargardt disease, an orphan disease affecting the retina, leading to blindness - **Prevalence**: Approximately 53,000 patients in the U.S., with a global prevalence of about 1 in 7,000, making it one of the top 10 most prevalent inherited diseases [4][8][5] Core Points and Arguments - **Mechanism of Action**: - Stargardt disease is caused by mutations in the ABCA4 gene, leading to toxic accumulation of all-trans retinal in photoreceptors [12][13] - Tinlarebant works by antagonizing the retinol binding protein (RBP4), reducing retinal delivery to the eye and thereby decreasing toxic accumulation [14][15] - **Clinical Trials**: - **Phase 1B/2 Trial**: Showed stabilization of vision over 2 years with a significant reduction in disease progression compared to natural history studies [21][22] - **Phase 3 DRAGON Trial**: Enrolled 104 patients, demonstrating a 36% reduction in the progression rate of definitely decreased autofluorescence (DDAF) lesions over 2 years, statistically significant with a P value of 0.0033 [27][28] - Secondary endpoint showed a 34% reduction in DAF lesions, also statistically significant [28] - **Safety Profile**: - Reported 6 serious adverse events, with none related to the drug. Common mild side effects included longer dark adaptation times and temporary visual discoloration [37][40] - **Regulatory Plans**: - Anticipated FDA submission in the first half of the year, with potential approval in the first quarter of the following year [43][44] - Plans for submissions to other global regulators, including EMA and PMDA in Japan, with a focus on a single trial for multiple regulatory approvals [45][46] Additional Important Information - **Market Opportunity**: Stargardt disease represents a significant unmet medical need, with no approved treatments currently available [8] - **Geographic Variability**: Prevalence of ABCA4 mutations varies globally, with the highest rates in populations of African descent [58][60] - **Future Studies**: Ongoing PHOENIX trial for geographic atrophy, with expectations to outperform existing therapies [66] - **Commercial Strategy**: Focus on genetic testing to confirm ABCA4 mutations, essential for patient eligibility for Tinlarebant [73] Conclusion Belite Bio is positioned to address a significant unmet need in the treatment of Stargardt disease with its innovative oral therapy, Tinlarebant, backed by promising clinical trial results and a clear regulatory pathway. The company is also preparing for commercialization and expanding its research into related conditions.

Cantor Fitzgerald raised the firm’s price target on Belite Bio (BLTE) to $266 from $200 and keeps an Overweight rating on the shares. Recent commentary suggested a possibility of a much higher WAC than the $200K/year the firm was modeling, the analyst tells investors in a research note. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today’s best-performing stocks on TipRanks >> Read More on BLTE: Disclaimer & DisclosureReport an Issue ...

Financial Data and Key Metrics Changes - For Q4 2025, R&D expenses were $14.6 million, up from $7.3 million in Q4 2024, primarily due to expenses related to the DRAGON II trial and lower Australian R&D tax incentives [9][10] - SG&A expenses increased to $13.5 million from $4.2 million in Q4 2024, driven by higher share-based compensation and professional service fees [11][12] - The net loss for Q4 2025 was $25.3 million, compared to a net loss of $10.1 million in Q4 2024 [12] - For the full year, R&D expenses were $45.4 million, up from $29.9 million in 2024, while SG&A expenses rose to $38.9 million from $10.1 million [13][14] - The full year net loss was $77.6 million, compared to a net loss of $36.1 million in 2024 [15] Business Line Data and Key Metrics Changes - The DRAGON trial met its primary efficacy endpoint with a 36% reduction in the growth rate of atrophy lesions compared to placebo, positioning the company for regulatory engagement [5] - Enrollment in the phase III PHOENIX trial was completed with 430 subjects [7] Company Strategy and Development Direction - The company aims for a transformative year in 2026, with a planned NDA submission to the FDA in Q2 2026 and commercialization preparations for Stargardt disease [8] - Key leadership positions have been filled, and the company is building its organization in various functions including sales and marketing [8] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the upcoming NDA submission and the potential for Tinlarebant to be the first approved therapy for Stargardt disease [4][8] - The company is focused on ensuring awareness among physicians and patients regarding the new treatment [33] Other Important Information - The company closed the year with $772.6 million in cash equivalents, significantly up from $145.2 million at the end of 2024, indicating a strong balance sheet [16] Q&A Session Summary Question: NDA submission and cash usage - The NDA will be a rolling submission, with DRAGON II data relevant for Japan only. The company expects R&D activities to cost about $150 million over the next three years, with commercialization costs between $150 million and $200 million [20][21] Question: Pricing guidance - While it's early to set a price, the average price for rare disease drugs in the US is around $350,000, and the company expects to perform better than that [25] Question: Launch timing and challenges - The expected launch is by Q1 2027, with a focus on genetic testing and patient awareness as key factors for success [32][33] Question: Ex-US regulatory strategy - The company prioritizes the FDA for NDA submission, with plans to follow up with EMA and other regions afterward [40][70] Question: Prevalence of Stargardt disease - The estimated prevalence of Stargardt disease in the US is about 53,000 patients, based on genetic databases [76][77]

Financial Data and Key Metrics Changes - For Q4 2025, R&D expenses were $14.6 million, up from $7.3 million in Q4 2024, primarily due to expenses related to the DRAGON II trial and lower Australian R&D tax incentives [7][8] - SG&A expenses increased to $13.5 million from $4.2 million in Q4 2024, driven by higher share-based compensation and professional service fees [8][9] - The net loss for Q4 2025 was $25.3 million, compared to $10.1 million in Q4 2024, while the non-GAAP net loss was $13.6 million, up from $5.9 million in Q4 2024 [9][10] - For the full year, R&D expenses totaled $45.4 million, compared to $29.9 million in 2024, and SG&A expenses were $38.9 million, up from $10.1 million in 2024 [9][10] - The company reported a full-year net loss of $77.6 million, compared to a net loss of $36.1 million in 2024, with a non-GAAP net loss of $38.7 million compared to $27.2 million in 2024 [10] Business Line Data and Key Metrics Changes - The DRAGON trial met its primary efficacy endpoint, showing a 36% reduction in the growth rate of atrophy lesions compared to placebo, which positions the company well for regulatory engagement [5][6] - Enrollment in the DRAGON II study reached 72 subjects, with expectations to finalize between 72 and 75 subjects [5] - The PHOENIX trial completed enrollment with 430 subjects [6] Company Strategy and Development Direction - The company aims for a transformative year in 2026, with a planned NDA submission to the FDA in Q2 2026 and ongoing commercialization preparations for Stargardt disease [6][11] - Key leadership positions have been filled, and the company is building its organization in various functions including sales and marketing [6] - The company expects to allocate approximately $150 million for R&D activities and $200 million for commercialization over the next three years [16] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the upcoming NDA submission and the potential for Tinlarebant to become the first approved therapy for Stargardt disease [4][6] - The company anticipates launching the product by Q1 2027, focusing on genetic testing and awareness among physicians [27][28] - Management believes that the absence of existing treatments for Stargardt disease will facilitate a straightforward launch [28] Other Important Information - The company completed a $402 million public offering in Q4, significantly strengthening its balance sheet with $772.6 million in cash equivalents at year-end [6][11] - The company is prioritizing the U.S. market for regulatory submissions, with plans to follow up with submissions in Europe and Japan [35][66] Q&A Session Summary Question: Is the NDA submission expected to be rolling, and what role will DRAGON II play? - Management confirmed that the NDA will be a rolling submission, with DRAGON II data specifically for Japan [15] Question: What are the expected uses of cash for trials and commercialization? - The company expects to spend about $150 million on R&D and $200 million on commercialization over the next three years [16] Question: Can you provide guidance on pricing for the drug? - Management indicated that while it's early to set a price, they expect it to be higher than the average rare disease drug price of $350,000 [20] Question: What is the expected launch timing after NDA submission? - The company anticipates launching by Q1 2027, with a focus on genetic testing and physician awareness [27][28] Question: What are the key gating items before NDA submission? - The primary gating item is the finalization of the clinical study report [22] Question: How important is visual acuity for approval and reimbursement? - Visual acuity is important for regulators, but management believes it may not be a realistic target for efficacy signals in Stargardt disease [55] Question: What is the true prevalence of Stargardt disease? - Management estimates about 53,000 patients in the U.S. are affected by ABCA4 mutated retinal disease, including Stargardt disease [71] Question: Are there plans to expand into the pediatric population? - The company has an approved pediatric investigational plan with EMA, set to initiate in April [74]

Financial Data and Key Metrics Changes - For Q4 2025, R&D expenses were $14.6 million, up from $7.3 million in Q4 2024, primarily due to DRAGON II trial expenses and lower Australian R&D tax incentives [6][8] - SG&A expenses increased to $13.5 million from $4.2 million in Q4 2024, driven by higher share-based compensation and professional service fees [8][10] - The net loss for Q4 2025 was $25.3 million, compared to $10.1 million in Q4 2024, while the non-GAAP net loss was $13.6 million, up from $5.9 million in Q4 2024 [8][9] - For the full year, R&D expenses totaled $45.4 million, compared to $29.9 million in 2024, and SG&A expenses were $38.9 million, up from $10.1 million in 2024 [9][10] - The full year net loss was $77.6 million, compared to $36.1 million in 2024, with a non-GAAP net loss of $38.7 million, up from $27.2 million in 2024 [10][11] Business Line Data and Key Metrics Changes - The company achieved significant milestones in 2025, including the successful phase 3 DRAGON trial, which demonstrated a 36% reduction in the growth rate of atrophy lesions compared to placebo [4][5] - Enrollment in the DRAGON II study reached 72 subjects, with expectations to finalize between 72 and 75 subjects [4] - The phase 3 PHOENIX trial in GA completed enrollment with 430 subjects [5] Market Data and Key Metrics Changes - The company closed the year with $772.6 million in cash equivalents, significantly up from $145.2 million at the end of 2024, positioning it well for future objectives [11] Company Strategy and Development Direction - The primary focus for 2026 is the planned NDA submission to the FDA in Q2 2026, with commercialization preparations for Stargardt disease already underway [5][6] - The company aims to build its organization in sales, market access, medical affairs, marketing, regulatory, and operations [6] - The company is prioritizing the U.S. market for regulatory submissions, with plans to follow up with EMA and other regions post-U.S. approval [33][59] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the upcoming year, highlighting the transformative potential of Tinlarebant as a treatment for Stargardt disease [3][5] - The management noted that the absence of existing treatments for Stargardt disease could facilitate a straightforward launch process [27] - The company anticipates launching by Q1 2027, with a focus on genetic testing and patient awareness as key factors for success [26][27] Other Important Information - The company completed a $402 million public offering in Q4 2025, which supports its commercialization and pipeline development efforts [5] - Management indicated that pricing for the drug is still under consideration, with expectations that it could exceed the average rare disease drug price of approximately $350,000 [19] Q&A Session Summary Question: NDA submission process and cash usage - The NDA will be a rolling submission, with DRAGON II data relevant only for Japan. The company expects to spend about $150 million on R&D activities and $150-$200 million on commercialization over the next three years [14][15] Question: Pricing guidance and NDA gating items - Pricing is still being determined, but the company expects to set a price higher than the average for rare disease drugs. The key gating item before NDA submission is the finalization of the clinical study report [19][21] Question: Launch timing and challenges - The company expects to launch by Q1 2027, with a sales team focused on genetic testing and brand awareness. Challenges include patient and physician awareness of the treatment [26][27] Question: Ex-U.S. regulatory strategy - The company prioritizes the U.S. FDA submission, with plans to follow up with EMA and other regions after securing U.S. approval [33][59] Question: Stargardt disease prevalence and awareness - The company estimates about 53,000 patients in the U.S. are affected by Stargardt disease, and having a treatment available is expected to increase awareness and diagnosis of undiagnosed patients [64][66] Question: Pediatric studies - The company has an approved pediatric investigational plan with EMA to study safety and efficacy in children aged 3 to 11, with plans to expand into the pediatric population [68][70]

Q4 and FYE 2025 Financial Results Conference Call March 2, 2026, 4:30 p.m. ET Nasdaq: BLTE For more info, please visit: www.belitebio.com Belite Bio Participants Belite Management Team Hao-Yuan Chuang, CFA, MBA, FRM (CFO) B E L I T E B I O / 2 Tom Lin, MMED, PhD, MBA (Chairman, CEO) Hendrik Scholl, MD, MA (CMO) Nathan Mata, PhD (CSO) • 16+ years of executive management roles in biotech • Over 10 new drug developments in multiple therapeutic areas including ophthalmology • University of Sydney, University of ...

SAN DIEGO, March 02, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the Company will participate in a fireside chat at the Leerink Global Healthcare Conference on Monday, March 9, 2026 at 1:00 pm ET. Webcast Link InstructionsA webcast of each presentation can be accessed under the "E ...

Core Insights - Belite Bio, Inc. reported positive topline results from its pivotal Phase 3 DRAGON trial for tinlarebant, a potential first-in-class therapy for Stargardt disease, and plans to submit a New Drug Application (NDA) to the FDA in Q2 2026 [2][5][6] Financial Highlights - As of December 31, 2025, the company had $352.9 million in cash and cash equivalents, a significant increase from $31.7 million on December 31, 2024 [9] - The company completed a $402 million public offering, with net proceeds aimed at supporting commercialization preparation and pipeline development [8] - Research and development expenses for Q4 2025 were $14.6 million, up from $7.3 million in Q4 2024, primarily due to costs associated with the DRAGON II trial [10] - Selling, general, and administrative expenses for Q4 2025 were $13.5 million, compared to $4.2 million in Q4 2024, driven by increased share-based compensation and professional service fees [12] - The company reported a GAAP net loss of $25.3 million for Q4 2025, compared to a net loss of $10.1 million for the same period in 2024 [16] Clinical Development Highlights - Tinlarebant is an oral RBP4 antagonist that reduces vitamin A delivery to the eye, addressing the toxic accumulation in Stargardt disease and geographic atrophy [3][4] - The DRAGON trial demonstrated a 35.7% reduction in the growth rate of macular lesions in adolescent STGD1 patients, achieving statistical significance [6] - The DRAGON II trial has completed enrollment with 72 subjects, targeting a total of 60 subjects, and aims to facilitate a future NDA submission in Japan [5][6] Corporate Developments - The company has received multiple designations for tinlarebant, including Breakthrough Therapy and Fast Track in the U.S., and Orphan Drug Designation in multiple regions [4] - Belite Bio is focused on advancing treatments for degenerative retinal diseases with significant unmet medical needs, including STGD1 and geographic atrophy [19]

Core Viewpoint - Belite Bio, Inc is set to host a webcast on March 2, 2026, to discuss its financial results and provide a business update for Q4 and the full year ended December 31, 2025 [1]. Company Overview - Belite Bio is a clinical-stage drug development company focused on creating novel therapeutics for degenerative retinal diseases with significant unmet medical needs, including Stargardt disease type 1 (STGD1) and geographic atrophy (GA) in advanced dry age-related macular degeneration (AMD) [3]. - The company's lead candidate, tinlarebant, is an oral therapy designed to reduce the accumulation of bisretinoid toxins in the eye [3]. - Belite Bio has completed a Phase 3 trial (DRAGON) in adolescent STGD1 subjects and is currently conducting a Phase 2/3 trial (DRAGON II) in the same demographic, as well as a Phase 3 trial (PHOENIX) in subjects with GA [3]. Webcast Information - The webcast will take place on March 2, 2026, at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) [2]. - A replay of the webcast will be available for approximately 90 days after the event [2].

Core Insights - Belite Bio, Inc is participating in the Asia-Pacific Academy of Ophthalmology (APAO) 2026 Congress to present findings related to its drug tinlarebant for Stargardt disease type 1 (STGD1) [1][2] Company Overview - Belite Bio is a clinical-stage drug development company focused on novel therapeutics for degenerative retinal diseases, including STGD1 and geographic atrophy (GA) in advanced dry age-related macular degeneration (AMD) [8] - The lead candidate, tinlarebant, is designed to reduce the accumulation of bisretinoid toxins in the eye, which are linked to retinal diseases [8] Upcoming Presentations - The company will present topline results from the Phase 3 DRAGON study of tinlarebant for adolescents with STGD1 during the APAO Congress [2][3] - An oral presentation is scheduled for February 6, 2026, and a sponsored lunch symposium will take place on February 7, 2026 [3] Exhibition Details - Belite Bio will have an exhibition booth at the APAO Congress from February 5-7, 2026, located at Hall 5E, Booth 5E-C03 [4] About Tinlarebant - Tinlarebant is an oral therapy that aims to reduce vitamin A-based toxins causing retinal disease in STGD1 and contributes to disease progression in GA [4] - The drug has received multiple designations, including Breakthrough Therapy and Fast Track in the U.S., and Orphan Drug Designation in the U.S., Europe, and Japan [4] About Stargardt Disease Type 1 (STGD1) - STGD1 is the most common inherited macular dystrophy, leading to central vision loss due to mutations in the ABCA4 gene [5] - There are currently no FDA-approved treatments for STGD1, highlighting the unmet medical need in this area [5]